Diane M Simeone, MD
Dr. Simeone's principal clinical interest is in the management of pancreatic neoplasms. Dr. Simeone has multiple NIH grants investigating the molecular mechanisms important in the development and progression of pancreatic adenocarcinoma and her laboratory was the first to identify pancreatic cancer stem cells. She also leads several studies focused on developing an early detection blood test for pancreatic cancer.
She has served as president of both the Society of University Surgeons and the American Pancreatic Association. Dr. Simeone is a member of the Institute of Medicine of the National Academy of Science and serves on the Scientific Advisory Board for the National Pancreas Foundation and the NCI Pancreatic Cancer Task Force.
1) Pancreatic cancer stem cells. Our group was the first to identify a highly tumorigenic subpopulation of pancreatic cancer cells that possess stem cell-like properties. These cells, which have the cell surface marker expression CD44+, CD24+, ESA+, account for approximately .5-1% of all human pancreatic cancer cells and have the ability to self-renew and generate the phenotypic heterogeneity of the primary tumor. We are currently studying the optimal marker(s) to identify human pancreatic cancer stem cells that can be used to measure cancer stem cell burden in human biopsy samples, determining therapeutic approaches to specifically target pancreatic cancer stem cells, and define the mechanisms by which these cells are resistant to standard therapies. http://www.cancer.med.umich.edu/pancreatic-cancer-research/simeone-lab-projects.shtml.
2) Understanding the role of ATDC in human pancreatic cancer. We have recently found that the majority of human pancreatic adenocarcinomas over-express the gene for Ataxia-Telangiectasia Group D Associated (ATDC). The ATDC gene was initially described in association with the genetic disorder ataxia-telangiectasia (AT) but was later found not to be the gene responsible for AT. We have identified ATDC as a novel DNA damage response gene that confers a survival advantage to pancreatic cancer cells when exposed to DNA damaging agents such as ionizing radiation and gemcitabine. We have shown that following DNA damage, ATDC traffics to the nucleus, is phosphorylated and localizes to DNA damage repair foci. Loss of ATDC results in increased sensitivity to gemcitabine- and radiation-induced apoptosis and a defect in downstream cell cycle checkpoint signaling. We have also found that high levels of ATDC confer a growth advantage to pancreatic cancer cells both in vitro and in vivo. The ATDC-mediated stimulation of cell proliferation may be due to enhancement of the β-catenin pathway since overexpression of ATDC increases β-catenin-mediated transcription. ATDC interacts with the HIT family protein HINT1, which is a negative regulator of the β-catenin pathway, and we hypothesize that ATDC stimulates β-catenin-mediated proliferation by sequestering HINT1. We are currently investigating the molecular mechanisms by which ATDC functions in the promotion of growth of pancreatic cancer cells as well as its role in the DNA damage response and resistance to standard therapies.
3) Investigating the role of TGFβ/Smad signaling in pancreatic growth regulation and tumorigenesis. TGFβ is an important regulator of growth inhibition in the pancreas and loss of this growth inhibitory function contributes to pancreatic tumorigenesis. We have recently reported an important crosstalk mechanism by which that TGFβ activates protein kinase A (PKA) by a cAMP-independent mechanism through Smad proteins. This interaction requires the formation of a trimeric complex between an activated Smad3/Smad4 complex and the regulatory subunit (R) of the PKA holoenzyme. We have defined the interaction domains of these 3 proteins and have discovered that PKA activation through interaction with Smads is critical in the regulation of many TGF&beta-mediated responses. We are currently testing if PKA regulates nucleocytoplasmic trafficking of Smads, and through this mechanism mediates TGFβ-regulated growth responses in pancreatic cells.
- Medical School or Training
- Duke University, 1988
- University of Michigan Health System, Surgery General, MI, 1995
- Board Certification